Recent approvals from clinical trials have demonstrated progress in combating resistance; the compact macrocyclic structure of repotrectinib avoids steric hindrance in cancer driven by the ROS1/NTRK fusion (NCT06315010), whereas pirtobrutinib (NCT03740529), a noncovalent BTK inhibitor, targets C481S mutations in CLL. This evidence concerns the gene BTK and cancer.